Oppenheimer Reiterates Outperform on UroGen Pharma, Maintains $40 Price Target

Benzinga · 10/16 13:17
Oppenheimer analyst Leland Gershell reiterates UroGen Pharma (NASDAQ:URGN) with a Outperform and maintains $40 price target.